>> Targeting EGF-1 might be an added benefit but it also reduces MTD and reduces HER-2 inhibition.
We are not talking about single agent here. Even if we do, oncology has been obsessed with MTD, resulting so many small companies with unnecessarily high so-called MTD - it is over rated for target agents especially in combination with similar agents, mechanism is more important than so-called MTD.
News 
Market Data 
Discover 
